ST Sinobioway Medicine: Tianjin Sinobioway is subject to other risk warnings
Sinobioway Medicine announced that its controlling subsidiary, Tianjin Sinobioway Biomedicine Co., Ltd., has been subjected to risk control measures that suspend production and sales, and it is expected that normal production and business activities cannot be resumed within three months. This triggers relevant provisions of the Shenzhen Stock Exchange Listing Rules. Starting from July 8, 2025, it will be subject to other risk warnings, and the stock abbreviation will be changed to "ST Sinobioway," with a daily price fluctuation limit of 5%
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments